28bio Introduces 3D Brain Organoids to Evaluate Anti-Inflammatory Therapies

28bio has launched CNS-3D Inflammatory Organoids to measure the effectiveness of anti-inflammatory drugs in central nervous system disorders, announced in a press release. The model quantifies how treatments reduce inflammatory injury, preserve tissue health, and restore neuronal network activity.

The organoids replicate human neuroimmune interactions by integrating neurons, astrocytes, and microglia into a single assay-ready system. They respond to pro-inflammatory stimuli such as TNF-alpha, LPS, and IL-6, allowing researchers to study functional disruption and cellular response in a human cortical tissue context.

Researchers can combine functional calcium imaging with cytokine analysis, immunostaining, and molecular profiling to obtain detailed data on neuroimmune activity and therapeutic outcomes. The organoids will be available in multiple replicate formats and as research services starting in the third quarter of 2026.

This release follows the company's earlier introduction of CNS-3D Myelinated Organoids, expanding its suite of human-based brain models for studying disease mechanisms and recovery processes.